Deals channel feed – Endpoints News

Deals channel feed

MeiraGTx teams with cryptic AI startup, co-founded by Eric Schmidt, to advance Parkinson's gene therapy

Last month

Acelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both companies

Last month

Updated: Endo and Mallinckrodt to merge in $6.7B deal

Last month

Mallinckrodt and Endo exploring a $7B merger — report

Last month

Ono licenses rare blood disease drug from Ionis for $280M upfront

2 months ago

Updated: Zealand partners with Roche on its amylin analog in a deal worth up to $5.3B

2 months ago

Endo sells international business for $84M

2 months ago

Bristol Myers buys out cell therapy partner 2seventy bio

2 months ago

Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody

2 months ago

Exclusive: Daiichi Sankyo, Johnson & Johnson partner with RNA delivery startup Nosis Bio

2 months ago

How bluebird's buyout offer went from $100M upfront to $29M

2 months ago

At $300M Kardigan startup, former MyoKardia team unveils its first drug, and it comes from Ionis

2 months ago

Walgreens to go private in $10B deal

2 months ago

No news is good news? Merck KGaA quiet on potential SpringWorks takeover

2 months ago

Updated: Jazz to buy Chimerix to get brain tumor drug five months ahead of PDUFA

2 months ago

Acelyrin rejects buyout offer from Tang’s Concentra, sticks to Alumis merger

2 months ago

Protagonist, Takeda's profit sharing deal under spotlight after Phase 3 blood disorder trial win

2 months ago

Novartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfront

2 months ago

Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanisms

2 months ago

ADCs from a decade-old Singapore biotech find new life with $187M

2 months ago

AbbVie finally enters obesity race with $350M upfront for Gubra’s amylin

2 months ago

BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen

2 months ago

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

2 months ago

Verve is latest gene editing company to suffer setback, as Vertex walks away from pact

2 months ago

First page Previous page 1 234 5 6 Next page Last page